Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III Clinical Trial

Rahimi et al., Jundishapur Journal of Natural Pharmaceutical Products, doi:10.5812/jjnpp-129817

Oct 2022

Source PDF All Studies Meta AnalysisMeta

RCT 40 ICU patients in Iran, showing lower mortality with NAC treatment, without statistical significance. Single dose intravenous NAC 300 mg/kg.

Although the 33% lower mortality is not statistically significant, it is consistent with the significant 23% lower mortality [7‑37%] from meta analysis of the 18 mortality results to date.

Important missing comments or errors? Let us know.

risk of death, 33.3% lower, RR 0.67, p = 0.19, treatment 10 of 20 (50.0%), control 15 of 20 (75.0%), NNT 4.0.

hospitalization time, 7.5% lower, relative time 0.92, p = 0.63, treatment 20, control 20.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Rahimi et al., 8 Oct 2022, Single Blind Randomized Controlled Trial, Iran, peer-reviewed, 10 authors.

All Studies All Outcomes Submit Updates or Corrections

This Paper N-acetylcys..All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0